Publications by authors named "Mark G Midei"

Claim this Profile
A
An expanded access protocol of RT001 in amyotrophic lateral sclerosis-Initial experience with a lipid peroxidation inhibitor.
Megan Yerton, Allison Winter, Anthony Kostov, Cassandra Lieberman, Dario Gelevski, Mark G Midei

Muscle Nerve· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electrophysiological and ECG Effects of Perhexiline, a Mixed Cardiac Ion Channel Inhibitor, Evaluated in Nonclinical Assays and in Healthy Subjects.
Mark G Midei, Borje Darpo, Greg Ayers, Randy Brown, Jean-Philippe Couderc

J Clin Pharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RT001 in Progressive Supranuclear Palsy-Clinical and In-Vitro Observations.
Plamena R Angelova, Kristin M Andruska, Mark G Midei, Mario Barilani, Paldeep Atwal

Antioxidants (Basel)· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease.
Detlef Albrecht, Mintu P Turakhia, Daniel Ries, Thomas Marbury, William Smith, Mark G Midei

Thromb Haemost· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant.
Detlef Albrecht, David Ellis, Daniel M Canafax, Daniel Combs, Pascal Druzgala, Mark G Midei

Thromb Haemost· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial.
Richard P Whitlock, Christopher B Fordyce, Mark G Midei, Dave Ellis, David Garcia

Thromb Haemost· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: final results of the ZoMaxx II trial.
William A Gray, Alan C Yeung, Donald E Cutlip, Jeffrey J Popma, Peter J Fitzgerald, Mark G Midei

Int J Cardiol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary interventions.
Mark G Midei, Vicki J Coombs, David R Lowry, Michael N Drossner, Kerry C Prewitt

Cardiology· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
David E Kandzari, Martin B Leon, Jeffrey J Popma, Peter J Fitzgerald, Charles O'Shaughnessy, Mark G Midei

J Am Coll Cardiol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease.
Alexandra J Lansky, Ricardo A Costa, Michael Mooney, Mark G Midei, Henry K Lui

J Am Coll Cardiol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study.
Victor L Serebruany, Mark G Midei, Alex I Malinin, Benjamin R Oshrine, David R Lowry

Arch Intern Med· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usefulness of a cobalt chromium coronary stent alloy.
Dean J Kereiakes, David A Cox, James B Hermiller, Mark G Midei, William B Bachinsky

Am J Cardiol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized multicenter trial comparing a new, low-pressure versus a conventional coronary stent: primary results from the CONSERVE trial.
Sorin J Brener, Mark G Midei, Dean Nukta, Dean J Kereiakes, David G Rizik

J Invasive Cardiol· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis